Moderna (MRNA) shares jumped more than 10% to lead S&P 500 gainers Tuesday, a day after the first bird-flu death was reported in the U.S. The biotech company is developing a vaccine for H5N1.
On Monday, the Centers for Disease Control and Prevention (CDC) said that it was "saddened by Louisiana's report that a person previously hospitalized with severe avian influenza A (H5N1) illness [had] passed away." The agency added that it was "not unexpected because of the known potential for infection with these viruses to cause severe illness and death."
As of Monday, there had "been 66 confirmed human cases of H5N1 bird flu in the United States since 2024 and 67 since 2022," the CDC added.
Moderna shares were up 12% at $47.50 in early-afternoon trading Tuesday. Despite the gain, the stock has lost more than half of its value over the past year and is well off its all-time high of nearly $500 in August 2021, during the height of the COVID-19 pandemic.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。